Sanofi to detail Relypsa' Patiromer FOS in USA

11 August 2015

US biotech firm Relypsa (Nasdaq: RLYP) has entered a two-year detailing agreement with French pharma major Sanofi (Euronext: SAN) for Patiromer for Oral Suspension (Patiromer FOS).

Patiromer FOS is Relypsa's investigational medicine that is currently under review for the treatment of hyperkalemia with the US Food and Drug Administration, with a Prescription Drug User Fee Act (PDUFA) action date of October 21, 2015. The same day, Relypsa announced a commercialization agreement for Europe and other territories outside the USA and Japan, with Switzerland-based Vifor Fresenius Medical care Renal Pharma (see separate story today), in a deal worth a potential $165 million to the US company.

Sanofi will complement Relypsa’s efforts

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK